Article
Biochemistry & Molecular Biology
Joana Barros-Martins, Swantje Hammerschmidt, Anne Cossmann, Ivan Odak, Metodi Stankov, Gema Morillas Ramos, Alexandra Dopfer-Jablonka, Annika Heidemann, Christiane Ritter, Michaela Friedrichsen, Christian Schultze-Florey, Inga Ravens, Stefanie Willenzon, Anja Bubke, Jasmin Ristenpart, Anika Janssen, George Ssebyatika, Gunter Bernhardt, Jan Muench, Markus Hoffmann, Stefan Poehlmann, Thomas Krey, Berislav Bosnjak, Reinhold Foerster, Georg M. N. Behrens
Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.
Article
Immunology
Rieke Reiter, Pia Von Blanckenburg, Reinier Mutters, Julia Thiemer, Reinhard Gessner, Ulf Seifart
Summary: This study investigated the influence of previous vaccination on the immune response to the booster. The results showed that the choice of previous vaccines did not affect the outcome of the booster vaccination, and antibody concentrations increased over time after vaccination.
Article
Multidisciplinary Sciences
Bruno Pozzetto, Vincent Legros, Sophia Djebali, Veronique Barateau, Nicolas Guibert, Marine Villard, Loic Peyrot, Omran Allatif, Jean-Baptiste Fassier, Amelie Massardier-Pilonchery, Karen Brengel-Pesce, Melyssa Yaugel-Novoa, Solene Denolly, Bertrand Boson, Thomas Bourlet, Antonin Bal, Martine Valette, Thibault Andrieu, Bruno Lina, Francois-Loic Cosset, Stephane Paul, Thierry Defrance, Jacqueline Marvel, Thierry Walzer, Sophie Trouillet-Assant
Summary: The study found that a heterologous vaccination regimen using ChAdOx1-S-nCoV-19 and BNT162b2 can provide better protection against SARS-CoV-2 infection with stronger neutralizing activity. This approach can activate memory B cells that recognize SARS-CoV-2, making it suitable for immunocompromised individuals.
Article
Virology
Emilie Catry, Julien Favresse, Constant Gillot, Jean-Louis Bayart, Damien Frerotte, Michel Dumonceaux, Patrick Evrard, Francois Mullier, Jonathan Douxfils, Francois M. Carlier, Melanie Closset
Summary: The immunogenicity of a two-dose ChAdOx1 nCoV-19 vaccine regimen was very poor in lung transplant recipients, but was significantly enhanced after the booster dose in one-third of the recipients. Immunosuppressants and high-dose corticosteroids were associated with a weak serological response.
Article
Medicine, General & Internal
Emanuel Vogel, Katharina Kocher, Alina Priller, Cho-Chin Cheng, Philipp Steininger, Bo-Hung Liao, Nina Korber, Annika Willmann, Pascal Irrgang, Juergen Held, Carolin Moosmann, Viviane Schmidt, Stephanie Beileke, Monika Wytopil, Sarah Heringer, Tanja Bauer, Ronja Brockhoff, Samuel Jeske, Hrvoje Mijocevic, Catharina Christa, Jon Salmanton-Garcia, Kathrin Tinnefeld, Christian Bogdan, Sarah Yazici, Percy Knolle, Oliver A. Cornely, Klaus Ueberla, Ulrike Protzer, Kilian Schober, Matthias Tenbusch
Summary: This study compared the dynamics of humoral and cellular immune responses up to 180 days after homologous or heterologous vaccination. The results showed that antibody responses significantly waned after vaccination, and heterologous vaccination resulted in stronger neutralization of SARS-CoV-2 and longer-lasting humoral immunity. All vaccination regimens induced stable, polyfunctional T-cell responses.
Article
Multidisciplinary Sciences
Eduardo Hermosilla, Ermengol Coma, Junqing Xie, Shuo Feng, Carmen Cabezas, Leonardo Mendez-Boo, Francesc Fina, Elisabet Ballo, Montserrat Martinez, Manuel Medina-Peralta, Josep Maria Argimon, Daniel Prieto-Alhambra
Summary: A cohort analysis from Catalonia shows that heterologous vaccination with ChAdOx1 followed by BNT162b2 has better vaccine effectiveness than two doses of ChAdOx1.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Markus Bauswein, David Peterhoff, Annelie Plentz, Andreas Hiergeist, Ralf Wagner, Andre Gessner, Bernd Salzberger, Barbara Schmidt, Stilla Bauernfeind
Summary: In this study, the neutralization capacity against the Delta variant of concern (VoC) was significantly increased in sera of participants who received a heterologous ChAdOx1 nCoV-19/BNT162b2 vaccine, especially in women with more severe adverse effects following the second immunization.
Article
Immunology
Yves Michiels, Nadhira Houhou-Fidouh, Gilles Collin, Jerome Berger, Evelyne Kohli
Summary: The study demonstrated that a MS patient treated with teriflunomide showed a strong humoral response after receiving a ChAdOx1 nCoV-19/ BNT162b2 vaccination regimen, indicating that the medication did not hinder the development of an effective immune response to the vaccine.
Article
Immunology
Louise Benning, Maximilian Toellner, Asa Hidmark, Matthias Schaier, Christian Nusshag, Florian Kaelble, Paula Reichel, Mirabel Buylaert, Julia Grenz, Gerald Ponath, Katrin Klein, Martin Zeier, Caner Susal, Paul Schnitzler, Christian Morath, Claudius Speer
Summary: This study demonstrates that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals.
Article
Virology
Tamiris Azamor, Ingrid Siciliano Horbach, Danielle Brito e Cunha, Juliana Gil Melgaco, Andrea Marques Vieira da Silva, Luciana Neves Tubarao, Adriana de Souza Azevedo, Renata Tourinho Santos, Nathalia dos Santos Alves, Thiago Lazari Machado, Jane Silva, Alessandro Fonseca de Souza, Camilla Bayma, Vanessa Pimenta Rocha, Ana Beatriz Teixeira Frederico, Brenda de Moura Dias, Bruno Pimenta Setatino, Caio Bidueira Denani, Samir Pereira da Costa Campos, Waleska Dias Schwarcz, Michel Vergne Sucupira, Edinea Pastro Mendes, Edimilson Domingos da Silva, Sheila Maria Barbosa de Lima, Ana Paula Dinis Ano Bom, Sotiris Missailidis
Summary: The study investigated immune responses to the ChAdOx1 nCoV-19 vaccine in COVID-19 and non-COVID-19 individuals, revealing significant differences in immune responses post-vaccination, with COVID-19 patients showing higher antibody levels and memory B cells. Vaccination was found to enhance IFN-γ production and impact the activation of T CD4+ naive cells in naive individuals.
Article
Immunology
Simone Barocci, Chiara Orlandi, Aurora Diotallevi, Gloria Buffi, Marcello Ceccarelli, Daniela Vandini, Eugenio Carlotti, Luca Galluzzi, Marco Bruno Luigi Rocchi, Mauro Magnani, Anna Casabianca
Summary: This study evaluated the post-vaccination humoral response in three real-world cohorts and found that a heterologous vaccine schedule induced a significantly higher humoral response. The type of vaccine was the main factor influencing antibody titer, and the study showed that using a heterologous vaccination strategy was safe with minimal side effects.
Article
Immunology
Simona Arientova, Katerina Matuskova, Oldrich Bartos, Michal Holub, Ondrej Beran
Summary: This study examined the dynamics and duration of immune responses after a three-dose regimen of the BNT162b2 mRNA vaccine. The results showed that the vaccine induced potent and enduring humoral and cellular immune responses, with enhanced protection after the third dose that remained stable up to a year later.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Marlene Pluess, Kemal Mese, Johannes T. Kowallick, Andreas Schuster, Desiree Tampe, Bjoern Tampe
Summary: As COVID-19 pandemic continues and new variants of SARS-CoV-2 emerge, there is an urgent need for vaccines to protect high-risk individuals and control disease outbreaks. Surveillance of rare safety issues related to these vaccines is underway. This article reports the first case of CMV reactivation and pericarditis associated with SARS-CoV-2 vaccination.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Jie Wei, Weiya Zhang, Michael Doherty, Zachary S. Wallace, Jeffrey A. Sparks, Na Lu, Xiaoxiao Li, Chao Zeng, Guanghua Lei, Yuqing Zhang
Summary: In a population-based study in the UK, the BNT162b2 vaccine showed higher efficacy than the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection and hospitalization for COVID-19, but there was no significant difference in the risk of death from COVID-19.
Article
Medicine, General & Internal
Gyungah Kim, Eun-Ji Choi, Han-Seung Park, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee
Summary: This case report describes a patient who developed ITP after receiving the AstraZeneca vaccine, with symptoms appearing 3 days after vaccination. Prompt clinical suspicion and appropriate treatment are essential for vaccine-related ITP.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2021)
Meeting Abstract
Gastroenterology & Hepatology
Milan Lukas, Martin Kolar, Martin Vasatko, Martin Lukas, Dana Duricova, Nadezda Machkova, Veronika Hruba, Karin Cerna, Kristyna Kastylova, Kristyna Kubickova
INFLAMMATORY BOWEL DISEASES
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Martin Lukas, Martin Kolar, Martin Vasatko, Milan Lukas
INFLAMMATORY BOWEL DISEASES
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Karin Cerna, Dana Duricova, Martin Lukas, Nadezda Machkova, Veronika Hruba, Milan Lukas
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Karin Cerna, Dana Duricova, Miroslav Hindos, Hrebackova Jana Hindos, Martin Lukas, Nadezda Machkova, Veronika Hruba, Katarina Mitrova, Kristyna Kubickova, Kristyna Kastylova, Vladimir Teplan, Milan Lukas
Summary: Limited knowledge on the immunogenicity of anti-SARS-CoV-2 vaccines in inflammatory bowel disease (IBD) patients. It was found that there was a more significant decrease in antibody levels in the IBD cohort compared to the healthy cohort after vaccination. Additionally, the overall functional ability of T-lymphocytes to produce interferon-gamma was lower in IBD patients. Repeated vaccine doses may be scheduled for IBD patients based on simple humoral and cellular post-vaccination monitoring.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Katarina Mitrova, Barbora Pipek, Martin Bortlik, Ludek Bouchner, Jan Brezina, Tomas Douda, Tomas Drasar, Pavel Klvana, Pavel Kohout, Vaclav Leksa, Petra Minarikova, Ales Novotny, Pavel Svoboda, Jan Skorpik, Jan Ulbrych, Marek Veinfurt, Blanka Zborilova, Milan Lukas, Dana Duricova
Summary: The safety of ustekinumab and vedolizumab treatment during pregnancy was evaluated in this study. The outcomes of pregnancy and postnatal infants were found to be favorable. Ustekinumab had a similar infant-to-maternal drug level ratio, while vedolizumab had an inverse ratio compared to anti-TNF preparations.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Karin Cerna, Dana Duricova, Martin Lukas, Martin Kolar, Nadezda Machkova, Veronika Hruba, Katarina Mitrova, Kristyna Kubickova, Marta Kostrejova, Jakub Jirsa, Kristyna Kastylova, Stepan Peterka, Gabriela Vojtechova, Milan Lukas
Summary: This study suggests that the subcutaneous formulation of infliximab (IFX-SC) may be more effective in treating Crohn's disease patients compared to intravenous infliximab. IFX-SC treatment was found to significantly improve the condition of refractory CD patients and had lower immunogenicity.
CROHNS & COLITIS 360
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Martin Lukas, Martin Kolar, Martin Vasatko, Milan Lukas
GASTROINTESTINAL ENDOSCOPY
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Karin Cerna, Dana Duricova, Martin Lukas, Nadezda Machkova, Veronika Hruba, Milan Lukas
Meeting Abstract
Gastroenterology & Hepatology
Martin Lukas, Martin Kolar, Martin Vasatko, Milan Lukas
Meeting Abstract
Gastroenterology & Hepatology
Milan Lukas, Martin Kolar, Martin Vasatko, Martin Lukas, Dana Duricova, Nadezda Machkova, Veronika Hruba, Karin Cerna, Kristyna Kastylova, Kristyna Kubickova